In triple-negative breast cancer (TNBC), targeted therapies based on overexpressed growth factor receptors (e.g., anti-epidermal growth factor receptor (EGFR) antibodies), loss of tumor suppressors (e.g., AKT inhibitors), and genomic instability (e.g., poly ADP ribose polymerase (PARP) inhibitors) have been utilized as strategies to improve therapeutic outcomes [5]. The gene discussed is EGFR; the disease is neoplasm.